Search results for "FIBROSIS"

showing 10 items of 901 documents

High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steato…

2011

Abstract Background and aim To investigate the hepatic expression of retinol-binding protein-4 (RBP4) in chronic hepatitis C (CHC) and nonalcoholic steatohepatitis (NASH) patients, and its association with biochemical and histological patterns of liver damage. Materials and methods Sixty-six genotype 1 CHC and 32 NASH patients were tested for hepatic RBP4 expression. Liver expression at immunostaining was scored as 0 (slight), 1 (mild), 2 (moderate), and 3 (intense). In addition, the mRNA and the quantitative protein expressions of RBP4 were tested by PCR and by western blot, respectively, in 12 NASH and 28 CHC patients. Twelve subjects undergoing elective cholecystectomy served as controls…

AdultMalemedicine.medical_specialtyLogistic ModelFibrosiHepatitis C virusInflammationSettore MED/08 - Anatomia Patologicamedicine.disease_causeGastroenterologyBody Mass IndexWestern blotFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineGenotypeMedicineHumansAge FactorRNA MessengerHEPATIC STEATOSISRetinol binding protein 4Settore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testbiologyNONALCOHOLIC STEATOHEPATITISbusiness.industryGastroenterologyAge FactorsHEPATITIS C VIRUSHepatitis C ChronicMiddle Agedmedicine.diseaseFibrosisFatty LiverLogistic Modelsbiology.proteinmedicine.symptomSteatosisInsulin ResistanceWaist CircumferenceRetinol binding protein-4businessRetinol-Binding Proteins PlasmaImmunostainingHumanDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Mature Survival Data for 176 Patients Younger Than 60 Years With Primary Myelofibrosis Diagnosed Between 1976 and 2005: Evidence for Survival Gains i…

2009

In the past 20 years, management of primary myelofibrosis (PMF) has incorporated new treatment approaches, but survival benefits have not been confirmed in controlled studies. This retrospective study includes 176 consecutive patients younger than age 60 years in whom PMF was diagnosed during a 30-year period (1976-2005). Median age at diagnosis was 50 years (range, 18-59 years), and 98 patients (55%) were men. At the time of this report, 99 patients (56%) had died; the 77 surviving patients were followed up for a median of 8 years (range, 4-24 years). Overall median survival was 9.2 years, and 15- and 20-year survival rates were 32% and 20%, respectively. According to the Dupriez Prognosti…

AdultMalemedicine.medical_specialtyMultivariate analysisTransplantation ConditioningAdolescentmedicine.medical_treatmentDiseaseHematopoietic stem cell transplantationKaplan-Meier EstimateDisease-Free SurvivalSettore MED/15 - Malattie Del Sanguemyelofibrosis survivalSurvival dataInternal medicinemedicineHumansMyelofibrosisSurvival rateProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelBrief ReportHematopoietic Stem Cell TransplantationRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyUnited StatesSurgerySurvival RatePrimary MyelofibrosisMultivariate AnalysisFemalebusiness
researchProduct

Automatic detection and quantification of ground-glass opacities on high-resolution CT using multiple neural networks: comparison with a density mask.

2000

We compared multiple neural networks with a density mask for the automatic detection and quantification of ground-glass opacities on high-resolution CT under clinical conditions.Eighty-four patients (54 men and 30 women; age range, 18-82 years; mean age, 49 years) with a total of 99 consecutive high-resolution CT scans were enrolled in the study. The neural network was designed to detect ground-glass opacities with high sensitivity and to omit air-tissue interfaces to increase specificity. The results of the neural network were compared with those of a density mask (thresholds, -750/-300 H), with a radiologist serving as the gold standard.The neural network classified 6% of the total lung a…

AdultMalemedicine.medical_specialtyOpacityAdolescentPulmonary FibrosisHigh resolutionSensitivity and SpecificityRadiographic image interpretationAbsorptiometry PhotonPredictive Value of TestsmedicineImage Processing Computer-AssistedHumansRadiology Nuclear Medicine and imagingProspective StudiesLungAgedAged 80 and overArtificial neural networkbusiness.industryFollow up studiesMean ageGeneral MedicinePneumoniaMiddle AgedSurgeryLung diseaseRadiographic Image Interpretation Computer-AssistedFemaleTomographyNeural Networks ComputerNuclear medicinebusinessTomography X-Ray ComputedFollow-Up StudiesAJR. American journal of roentgenology
researchProduct

Evaluation of serum copper and iron levels among oral submucous fibrosis patients

2010

Objective: To estimate and compare the levels of serum copper and iron among subjects with oral submucous fibrosis (OSMF) of different clinical stages and healthy controls. Study Design: Study sample comprised of 50 patients clinically diagnosed with OSMF and 50 healthy controls who were matched for age and gender. OSMF patients were categorised by clinical staging. Serum estimation of copper and iron was done using atomic absorbtion spectrophotometry. Results: Mean copper and iron level differed significantly (p<0.000) between the patients and controls with patients exhibiting higher copper (134.1±20.16) and lower iron (114.78±23.47) levels in contrast to controls who presented lower coppe…

AdultMalemedicine.medical_specialtyPathologyAdolescentIronSerum copperchemistry.chemical_elementOral Submucous FibrosisGastroenterologyLesionYoung AdultInternal medicinemedicineHumansStage (cooking)Young adultGeneral Dentistrybusiness.industryIron levelsBuccal administrationMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]CopperOtorhinolaryngologyOral submucous fibrosischemistryUNESCO::CIENCIAS MÉDICASSurgeryFemalemedicine.symptombusinessCopper
researchProduct

An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers

2009

Summary.  Liver biopsy is frequently required in HBeAg-negative disease to determine the stage of fibrosis. It can be difficult to distinguish cohorts with undetectable HBeAg who may have varying degrees of fibrosis due to different stages of disease. We have assessed the utility of transient elastography (TE) to evaluate differences in HBeAg-negative patients. A total of 220 HBsAg-positive individuals were studied: 125 (group 1) had an inactive HBsAg carrier state and 95 (group 2) were HBeAg-negative, anti-HBe-positive patients with persistently or intermittent elevation of alanine aminotransferase (ALT) and/or HBV DNA >105 copies/mL. Mean stiffness was 4.83 ± 1.2 kPa in group 1 vs 8.53 ± …

AdultMalemedicine.medical_specialtyPathologyHepatitis B virusBiopsymedicine.disease_causeGastroenterologyDiagnosis DifferentialYoung Adultfibroscan hepatitis B hepatitis B virus transient elastography type B hepatitis HBeAgFibrosisVirologyInternal medicineBiopsymedicineHumansHepatitis B e AntigensHepatitis B AntibodiesAgedHepatitis B virusHepatitis B Surface AntigensHepatologymedicine.diagnostic_testbusiness.industryvirus diseasesAlanine TransaminaseHepatitis BMiddle Agedmedicine.diseaseHepatitis Bdigestive system diseasesInfectious DiseasesCross-Sectional StudiesFibroscan; hepatitis B virus; transient elastography; type B hepatitis HBeAgHBeAgLiverLiver biopsyCarrier StateElasticity Imaging TechniquesFemalebusinessTransient elastographyViral hepatitis
researchProduct

Sudden death due to cardiac sarcoidosis in a case of suspected homicide

1993

In a case of suspected homicide death due to natural causes — cardiac death (SCD) — was found at autopsy. Despite an extensive replacement of myocardial tissue by sarcoid granulomata there was no history of cardiac dysfunction or preceding symptoms. The transmurally infiltrating granulomata and the concomitant fibrosis were predominantly confluent. They occupied vast areas within the interventricular septum and the adjacent posterior wall of the left ventricle. The only other organs involved were mediastinal lymph nodes, which appeared macroscopically normal.

AdultMalemedicine.medical_specialtyPathologySarcoidosisAutopsySudden deathPathology and Forensic MedicineDiagnosis DifferentialHomicideFibrosishemic and lymphatic diseasesInternal medicineHumansMedicineInterventricular septumbusiness.industryMyocardiummedicine.diseaseDeath Sudden Cardiacmedicine.anatomical_structureVentricleConcomitantCardiologyLymphCardiomyopathiesHomicidebusinessEndocardiumInternational Journal of Legal Medicine
researchProduct

The Incidence of Myelofibrosis in Essential Thrombocythaemia, Polycythaemia vera and Chronic Idiopathic Myelofibrosis: A Retrospective Evaluation of …

2004

The incidence of myelofibrosis (MF) among the three major Philadelphia chromosome-negative chronic myeloproliferative disorders, i.e. essential thrombocythaemia (ET), polycythaemia vera (PV) and chronic idiopathic myelofibrosis (CIMF), is not well documented since the diagnostic criteria have recently been redefined by the WHO. Therefore we performed a retrospective analysis of follow-up biopsies of 275 patients with ET, PV and CIMF according to the WHO classification of chronic myeloproliferative disorders. In the diagnostic bone marrow biopsies, MF was observed in 57 of the 136 CIMF patients (42%), 4 of the 73 PV patients (5%) and none of the 66 patients with ET. Within a median observati…

AdultMalemedicine.medical_specialtyPolycythaemiaIdiopathic myelofibrosisAdolescentBiopsyPhiladelphia chromosomeGastroenterologyBone Marrowhemic and lymphatic diseasesInternal medicineBiopsymedicineHumansPhiladelphia ChromosomeMyelofibrosisPolycythemia VeraAgedRetrospective Studiesmedicine.diagnostic_testbusiness.industryIncidenceIncidence (epidemiology)Retrospective cohort studyHematologyGeneral MedicineMiddle Agedmedicine.diseasemedicine.anatomical_structurePrimary MyelofibrosisFemaleBone marrowbusinessThrombocythemia EssentialActa Haematologica
researchProduct

Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program

2019

BACKGROUND Lifestyle modifications remain the cornerstone of treatment in non-alcoholic fatty liver disease (NAFLD). However, they requently fail related to the inability of patients to implement lasting changes. AIMS To evaluate the effects of a short, web-based, individualised exercise program on non-invasive markers of hepatic steatosis, inflammation and fibrosis. METHODS Patients with histologically confirmed NAFLD underwent an 8-week, web-based, individualised exercise program that contained bidirectional feedback. RESULTS Forty-four patients entered the study and 41 completed the assigned training goal (93.2%). In the completer population, 8 weeks of individualised exercise increased …

AdultMalemedicine.medical_specialtyPopulationGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineMedicineHumansPharmacology (medical)030212 general & internal medicineYoung adultExercise physiologyPrecision MedicineeducationExerciseLife Styleeducation.field_of_studyInternetHepatologybusiness.industryFatty liverGastroenterologyMiddle Agedmedicine.disease3. Good healthExercise TherapyQuality of LifeElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleSteatosisbusinessHepatic fibrosisTransient elastographyBiomarkersAlimentary Pharmacology & Therapeutics
researchProduct

Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents

2013

Abstract Background In chronic genotype 1 hepatitis C, telaprevir or boceprevir plus peginterferon and ribavirin have become the new standard of care. Aim of this study was to identify factors contributing to the decision whether to defer or treat with the current triple regimens. Methods Prospective assessment of eight parameters on 0-4-point scales by the attending physician at a German tertiary referral centre between 1st September 2011 and 31st December 2012. Results 307 patients were evaluated at least once by one of the 11 hepatologists involved; 267 patients were considered, but only 163 were recommended to receive triple therapy. Multivariate regression analysis revealed that a high…

AdultMalemedicine.medical_specialtyTime FactorsProlineDecision MakingHepacivirusPharmacologyAntiviral AgentsSeverity of Illness IndexPolyethylene GlycolsTelaprevirCohort Studieschemistry.chemical_compoundFibrosisBoceprevirInternal medicineDrug DiscoveryRibavirinGenotypemedicineHumansDecompensationProspective StudiesWatchful WaitingAgedDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaPatient PreferenceHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseLogistic ModelschemistryTolerabilityMultivariate AnalysisDisease ProgressionDrug Therapy CombinationFemalebusinessOligopeptidesmedicine.drugDigestive and Liver Disease
researchProduct

Survival in young patients with intermediate-/high-risk myelofibrosis: Estimates derived from databases for non transplant patients

2009

Recent studies have suggested that allogenic stem cell transplantation (allo-SCT) might be a better treatment option, compared to drug therapy, for young patients with high-/intermediate-risk primary myelofibrosis (PMF). However, there are no controlled studies that validate this contention and allo-SCT is associated with a substantial risk of procedure-related mortality and morbidity. In a retrospective analysis of nontransplant PMF patients, who were both young (age <60 years) and with high-/intermediate-risk disease, 1- and 3-year survival estimates were 87% and 55%, 95% and 77%, 71% and 58%, respectively, involving patients seen at three different centers with expertise in PMF; these da…

AdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentbone marrow transplantationContext (language use)myelofibrosisHematopoietic stem cell transplantationKaplan-Meier EstimateSettore MED/15 - Malattie Del Sanguemyelofibrosis survivalYoung AdultPharmacotherapyInternal medicinemedicineHumansTransplantation HomologousYoung adultMyelofibrosisRetrospective Studiesbusiness.industryAge FactorsHematopoietic Stem Cell TransplantationRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseSurgeryTransplantationmyelofibrosis; bone marrow transplantationPrimary MyelofibrosisFemaleTransplantation ConditioningbusinessFollow-Up Studies
researchProduct